Literature DB >> 15700388

Factors influencing response to disease modifying antirheumatic drugs in patients with rheumatoid arthritis.

Samantha L Hider, Caitriona Buckley, Alan J Silman, Deborah P M Symmons, Ian N Bruce.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15700388

Source DB:  PubMed          Journal:  J Rheumatol        ISSN： 0315-162X            Impact factor:   4.666


× No keyword cloud information.
  12 in total

Review 1.  Three decades of low-dose methotrexate in rheumatoid arthritis: can we predict toxicity?

Authors:  Vasco C Romão; Aurea Lima; Miguel Bernardes; Helena Canhão; João Eurico Fonseca
Journal:  Immunol Res       Date:  2014-12       Impact factor: 2.829

2.  Anti-tumour necrosis factor alpha therapy: can we afford it?

Authors:  D P M Symmons
Journal:  Ann Rheum Dis       Date:  2005-07       Impact factor: 19.103

3.  Current smoking status is associated to a non-ACR 50 response in early rheumatoid arthritis. A cohort study.

Authors:  Jorge Rojas-Serrano; Leticia Lino Pérez; Conrado García García; Francisco Moctezuma; Everardo Álvarez-Hernández; Janitzia Vázquez-Mellado; José Luis Montiel; Rubén Burgos-Vargas
Journal:  Clin Rheumatol       Date:  2011-05-24       Impact factor: 2.980

4.  Methotrexate impact on radiographic progression in biologic-treated rheumatoid arthritis under clinical remission: A case report on monozygotic Caucasian twins.

Authors:  Tomas Soukup; Jana Nekvindova; Martin Dosedel; Jindra Brtkova; Jan Toms; Drahomira Bastecka; Petr Bradna; Jiri Vlcek; Petr Pavek
Journal:  Int J Immunopathol Pharmacol       Date:  2016-10-21       Impact factor: 3.219

Review 5.  Efficacy of methotrexate in reducing the risk of bone erosion in patients with rheumatoid arthritis: a systematic review of randomized controlled trials.

Authors:  D P Destiani; S Naja; S Dewi; A R Rahmadi; S A S Sulaiman; R Abdulah
Journal:  Osteoporos Int       Date:  2020-11-18       Impact factor: 4.507

6.  Suppression and resolution of autoimmune arthritis by rhesus θ-defensin-1, an immunomodulatory macrocyclic peptide.

Authors:  Justin B Schaal; Dat Q Tran; Akshay Subramanian; Reshma Patel; Teresina Laragione; Kevin D Roberts; Katie Trinh; Prasad Tongaonkar; Patti A Tran; Dmitriy Minond; Gregg B Fields; Paul Beringer; André J Ouellette; Percio S Gulko; Michael E Selsted
Journal:  PLoS One       Date:  2017-11-16       Impact factor: 3.240

Review 7.  Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs?

Authors:  Vasco Crispim Romão; Helena Canhão; João Eurico Fonseca
Journal:  BMC Med       Date:  2013-01-23       Impact factor: 8.775

8.  Prediction of methotrexate clinical response in Portuguese rheumatoid arthritis patients: implication of MTHFR rs1801133 and ATIC rs4673993 polymorphisms.

Authors:  Aurea Lima; Joaquim Monteiro; Miguel Bernardes; Hugo Sousa; Rita Azevedo; Vitor Seabra; Rui Medeiros
Journal:  Biomed Res Int       Date:  2014-05-21       Impact factor: 3.411

9.  Chromosome conformation signatures define predictive markers of inadequate response to methotrexate in early rheumatoid arthritis.

Authors:  Claudio Carini; Ewan Hunter; Aroul S Ramadass; Jayne Green; Alexandre Akoulitchev; Iain B McInnes; Carl S Goodyear
Journal:  J Transl Med       Date:  2018-01-29       Impact factor: 5.531

Review 10.  Current Understanding of an Emerging Role of HLA-DRB1 Gene in Rheumatoid Arthritis-From Research to Clinical Practice.

Authors:  Tomasz Wysocki; Marzena Olesińska; Agnieszka Paradowska-Gorycka
Journal:  Cells       Date:  2020-05-02       Impact factor: 6.600
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.